| 1.69 -0.05 (-2.87%) | 12-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.24 | 1-year : | 2.61 |
| Resists | First : | 1.91 | Second : | 2.24 |
| Pivot price | 1.69  |
|||
| Supports | First : | 1.62 |
Second : | 1.44 |
| MAs | MA(5) : | 1.71 |
MA(20) : | 1.69 |
| MA(100) : | 1.52 |
MA(250) : | 1.07 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.9 |
D(3) : | 48.9 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 2.54 | Low : | 0.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CMMB ] has closed above bottom band by 46.6%. Bollinger Bands are 56.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.63 - 1.65 | 1.65 - 1.66 |
| Close: | 1.67 - 1.69 | 1.69 - 1.71 |
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Tue, 03 Dec 2024
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit - Quantisnow
Tue, 03 Dec 2024
Chemomab Therapeutics to Present at Oppenheimer's Rare Disease Summit - StockTitan
Tue, 19 Nov 2024
Chemomab's CM-101 Shows Promising Phase 2 Results in PSC Treatment Trial | CMMB Stock News - StockTitan
Thu, 14 Nov 2024
Chemomab Therapeutics CEO Dr Adi Mor discusses Q3 results; progress with lead PSC treatment | NASDAQ:CMMB - Proactive Investors USA
Thu, 14 Nov 2024
Chemomab Advances PSC Drug After Positive Phase 2 Results, Secures $10M Funding | CMMB Stock News - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 170 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 27.9 (%) |
| Shares Short | 163 (K) |
| Shares Short P.Month | 72 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.2 % |
| Return on Equity (ttm) | -93.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -1.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|